Login
Navigate Fool.com
Will INSM beat
the market?

INSMED, INC. (NASDAQ: INSM)

Community Rating: 2 Stars: Unattractive

17.70 -0.04 (-0.23%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $17.83
Previous Close $17.74
Daily Range $17.59 - $18.18
52-Week Range $10.16 - $22.29
Market Cap $695.1M
P/E Ratio -11.59
Dividend (Yield) $0.00 (0.0%)
Volume 432,380
Average Daily Volume 1,149,358
Current FY EPS -$1.79

How do you think INSM
will perform against the market?

Top INSM Bull/Bear Pitches

 

scrubs62074 (< 20)
Submitted February 12, 2013

High Volume Breakout on 02/12/13

0 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted July 15, 2013

Interestingly, I didn't even have enough time to register my negative feelings about Insmed's valuation before the company rushed to concur with me by arranging a 60M dilutive financing even though th … More

1 Replies Reply Report this Post

News & Commentary Rss Feed

This Week in Biotech: A Double-Dose of Hot Potato

Two pharma giants walk away from collaborations, another investigational drug receives the breakthrough designation, and more M&A activity are this week's biggest biotech stories.

3 Stocks That Soared Stupendously This Week

It was up, up, and away for these three stocks over the past week.

Why Insmed, Plug Power, and Ballard Power Systems Are Today's 3 Best Stocks

The FOMC meeting takes center stage and pushes the S&P 500 to a new record high, as Insmed, Plug Power, and Ballard Power Systems soar by double-digit percentages.

Mid-Afternoon Market Update: Fed Tapers Another $10B; Will Purchase $15B/Month Of MBS & $20B Per Mon

Mid-Afternoon Market Update: Fed Tapers Another $10B; Will Purchase $15B/Month Of MBS & $20B Per Month Of Treasuries

Why Insmed Incorporated Shares Skyrocketed

Insmed shares soar after the Food and Drug Administration grants its lead drug a special designation.

Sector Update: Healthcare Stocks Little Changed; Insmed Jumps Over 39% Following Positive Trial Resu

Sector Update: Healthcare Stocks Little Changed; Insmed Jumps Over 39% Following Positive Trial Results for Lung Drug

Wednesday’s Top Biotech Stories: Insmed, Endocyte, and GW Pharmaceuticals

Insmed, Endocyte, Merck, and GW Pharmaceuticals could all loom large in biotech headlines this Wednesday morning.

This Week in Biotech: PTC Therapeutics Surprises, Isis' Data Dazzles, and Provectus Sinks

Four positive clinical updates, a billion-dollar licensing deal, a surprising positive opinion for one company in the EU, and a rough NYSEArca debut for one biopharma are this week's top biotech stories.

Up 7%: Insmed's Data Still Mixed

Insmed noted some good news in culture conversion, but is that really the big takeaway?

Healthcare Stocks Lower Ahead of Tuesday Close; Insmed Rallies after Lung Drug Shows More Promise

See More INSM News...

Sector

Healthcare

Industry

Drugs

INSMED, INC. (INSM) Description

A biopharmaceutical company focused on the development and commercialization of drugs to treat metabolic diseases, endocrine disorders and oncology within niche markets that have unmet medical needs. Website: http://www.insmed.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks